Hydrofurimazine is a NanoLuc substrate whose enhanced aqueous solubility allows delivery of higher doses to mice. Hydrofurimazine enables sensitive bioluminescence imaging for either prolonged light production of high sensitivity.

ViviRen is a synthetic analog of coelenterazine specifically designed for bioluminescence imaging (BLI), offering enhanced performance in visualizing biological processes.

pyCTZ (Pyridyl CTZ) TFA, a pyridyl-modified derivative of Coelenterazine (CTZ), serves as an ATP-independent substrate for LumiLuc luciferase. This compound produces intense blue bioluminescence upon interaction with luciferases and is particularly effective in aequorin-based calcium sensing applications.

Furimazine, an imidazopyrazinone-based substrate, generates exceptionally bright luminescence when paired with NanoLuc (Nluc). This combination produces a 2.5 million-fold increase in light output compared to the Oluc-19 and Coelenterazine system in mammalian cells.

Coelenterazine is a luminescent enzyme substrate, used for monitoring reporter genes in BRET, ELISA and HTS techniques.

Coelenterazine E serves as a bioluminescent probe, widely utilized for its ability to emit light in biological and chemical applications.

Coelenterazine h, a modified form of Coelenterazine, exhibits heightened sensitivity to Ca2+ compared to the native compound, making it an effective tool for detecting subtle fluctuations in Ca2+ concentrations.

pyCTZ (Pyridyl CTZ) hydrochloride, a pyridyl derivative of Coelenterazine (CTZ), functions as an ATP-independent substrate for LumiLuc luciferase. This compound produces intense blue bioluminescence when interacting with luciferases and is particularly useful in aequorin-based calcium sensing applications.

Coelenteramine 400a (Bisdeoxycoelenterazine), a structural analog of Coelenterazine, serves as a substrate for Renilla luciferase (RLuc). When interacting with Coelenteramine 400a, RLuc catalyzes the emission of blue light with a peak wavelength of 395 nm.

DOCK5-IN-C21 functions as an allosteric inhibitor targeting the guanine nucleotide exchange factor DOCK5, effectively modulating its activity through a non-competitive mechanism.

VU0466551 is a targeted activator that specifically modulates homomeric G protein-gated inwardly rectifying potassium (GIRK1) channels, demonstrating its selectivity for this ion channel subtype.

Duvelisib (IPI-145) is a selective inhibitor of the p110δ isoform, exhibiting IC50 values of 2.5 nM, 27.4 nM, 85 nM, and 1602 nM for p110δ, p110γ, p110β, and p110α, respectively, highlighting its specificity and potency.

GL67 (N4-Spermine cholesteryl carbamate) is a cationic lipid widely utilized for the delivery of nucleic acid agents, vaccines, and gene transfection due to its efficient carrier properties. At equal molar concentrations, the salt and free forms of a compound typically demonstrate similar biological activity. However, the salt form often offers superior water solubility and improved stability, making it more practical for various applications.

ZYS-1 has inhibition effect on RNA adenosine deaminase 1(ADAR1), and can be used for preventing and/or treating cancer or tumor-related diseases.

AM-9747 is an MTA-cooperative PRMT5 inhibitor with IC50 of 9.5 nM in the MTAP-del viability assay and shows outstanding 75-fold selectivity over the corresponding isogenic MTAP-WT cellular viability. AM-9747 also shows a significant oral antitumor effect in mouse models employing PDXs.

UNC9426 is a novel and potent TYRO3 inhibitor with IC50 of 2.1 nM and Ambit selectivity score (S50 (1.0 μM) = 0.026), respectively. UNC9426 shows favorable pharmacokinetic properties in mice.

TH35 is a novel class of CRBN-recruiting cGAS-targeting PROTAC degrader with IC50 of 1.8 and 4.8 μM,in THP1-Lucia ISG and RAW-Lucia ISG cells, respectively. TH35 exhibits strong anti-inflammatory effects in the DSS-induced UC mice model.

1,2-O-Dioctadecyl-sn-glycerol (Compound 7b) is a lipid-based molecule that serves as a key component in the synthesis of thermostable lipid nanoparticles, enhancing their stability and functionality.

COTI-2 is a small molecule candidate anti-cancer drug which can convert mutant p53 to wild-type conformation.

Acoramidis (AG10) is an orally administered, highly selective kinetic stabilizer effective for both wild-type and V122I-TTR (transthyretin) variants. It is actively investigated as a therapeutic agent in the treatment of transthyretin amyloidosis.

Giloralimab (ABBV-927) is a potent antiCD40 agonistic monoclonal antibody. Giloralimab has the potential for the research of cancer.

Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research.

Ravagalimab (ABBV-323) is a CD40 antagonist (EC50: 3.7 nM). Ravagalimab can be used for research of Crohn's disease.

Dacetuzumab (SGN-40) is a humanized IgG1, anti-CD40 monoclonal antibody with anti-lymphoma activity. Dacetuzumab kills tumor cells via immune effector functions (antibody-dependent cellular cytotoxicity and phagocytosis [ADCC/ADCP]). Dacetuzumab ((SGN-40) can be used for multiple myeloma research.

Selicrelumab is an agonist CD40 antibody, induces changes in the tumor microenvironment. Selicrelumab can be used for the research of pancreatic cance and neoadjuvant study.

Sotigalimab, a CD40 agonistic monoclonal antibody. Sotigalimab binds CD40 with high affinity and activates antigen-presenting cells, thereby stimulating cancer-specific T cell responses. Sotigalimab is mainly used in the study of metastatic pancreatic cancer and metastatic melanoma.

Cudarolimab (IBI101) is a completely human anti-OX40 (CD134, a co stimulating molecule expressed by activated immune cells) antibody. Cudarolimab inhibits the binding of OX40 to its ligand OX40L. Cudarolimab has antitumor activity and can be used in cancer related research.